EATONTOWN, N.J., March 24 /PRNewswire-FirstCall/ -- Osteotech, Inc.
(Nasdaq: OSTE), a leader in the emerging field of biologic solutions for
regenerative medicine, announced today that the United States Patent and
Trademark Office has confirmed the validity of its U.S. Patent No.
5,676,146. The '146 patent covers mixtures of a radiolucent material, such
as demineralized bone, with a radiopaque material, such as nondemineralized
or partially demineralized bone, that is provided in sufficient quantity to
be used as a radiographic marker. The Patent Office's reexamination
certificate also includes four new claims.
"We are pleased that the United States Patent Office has confirmed the
validity of our '146 patent," said Sam Owusu-Akyaw, Osteotech's President
and Chief Executive Officer. "The '146 patent is an important part of our
strategic vision providing patent protection for certain of our current
Grafton(R) DBM products and for our next generation DBM products currently
under development. It is our patent protection that allows us to make the
investments necessary to continue to develop superior products for the
medical community and patient care."
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global
leader in providing OsteoBiologic solutions for regenerative medicine to
support surgeons and their patients in the repair of the musculoskeletal
system through the development of innovative therapy-driven products that
alleviate pain, promote biologic healing and restore function. For further
information regarding Osteotech, this press release or the conference call,
please go to Osteotech's website at http://www.osteotech.com.
Certain statements made throughout this press release that are not
historical facts contain forward-looking statements (as such are defined in
the Private Securities Litigation Reform Act of 1995) regarding the
Company's future plans, objectives and expected performance. Any such
forward-looking statements are based on assumptions that the Company
believes are reasonable, but are subject to a wide range of risks and
uncertainties and, therefore, there can be no assurance that actual results
may not differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to
differ materially include, but are not limited to, the Company's ability to
develop and introduce new products, differences in anticipated and actual
product and service introduction dates, the ultimate success of those
products in the marketplace, the continued acceptance and growth of current
products and services, the impact of competitive products and services, the
availability of sufficient quantities of suitable donated tissue and the
success of cost control and margin improvement efforts. Certain of these
factors are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission. All information in this
press release is as of March 24, 2008 and the Company does not intend to
update this information.
SOURCE Osteotech, Inc.
 back to top
Related links:
http://www.osteotech.com
http://www.prnewswire.com/comp/668050.html /
CONTACT:
Mark H. Burroughs of Osteotech, Inc.,
+1-732-542-2800
|
